Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer
Open accessAbstract
Learning Objectives: Explain the prognostic value of baseline CTCs. Describe the predictive value of CTCs at day 21 after chemotherapy. Explain the meaning of the change of CTCs from baseline to day 21 after chemotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Martin M. et al. observed a considerable decline in CTC-positive rate after chemotherapy in 117 breast cancer patients.
“Martin M. et al. assessed the variations in CTCs in 117 breast cancer patients and observed a considerable decline in CTC-positive rate after chemotherapy [149].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [149]
The CTC Enumeration results show a decline in patients with at least five CTCs after the first chemotherapy cycle: 47 at baseline versus 28 on day 21. However, the Results (p. 918) say 117 patients were initially registered, while only 99 had evaluable CTC measurements; the decline was not assessed in all 117. (LLM, conf=0.91)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602 · see citing works
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E. C., Miller, M. C., Matera, J., Repollet, M., Doyle, G. V., Terstappen, L. W. M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1769 · Cited by 776 · see citing works
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Liu, M., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M. J., Ottaviano, Y. L., Rao, S. B., Eng‐Wong, J., Seillier‐Moiseiwitsch, F., Noone, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6664 · Cited by 319 · see citing works
Pierga, J., Hajage, D., Bachelot, T., Delaloge, S., Brain, E. G. C., Campone, M., Dieras, V. C., Rolland, E., Mignot, L., Mathiot, C., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr263 · Cited by 281 · see citing works
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.016 · Cited by 235 · see citing works
Pierga, J., Bonneton, C., Vincent‐Salomon, A., de Crémoux, P., Nos, C., Blin, N., Pouillart, P., Thiery, J. P., & Magdelénat, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0102-03 · Cited by 223 · see citing works
Giordano, A., Giuliano, M., Laurentiis, M. D., Arpino, G., Jackson, S. A., Handy, B. C., Ueno, N. T., Andreopoulou, E., Alvarez, R. H., Valero, V., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr434 · Cited by 102 · see citing works
Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis.
Martín, M., García-Sáenz, J. Á., Casas, M. L. M. D. L., Vidaurreta, M., Puente, J., Veganzones, S., Lajusticia, L. R., de la Orden, V., Oliva, B., de la Torre, J., et al. (2009) · PubMed · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [5]5. Martín M, García-Saenz JA, Maestro ML et al. Circu- lating tumor cells in metastatic breast cancer: timing of blood extraction. Anticancer Res 2009;29:4185-4187.
Cited by
Sorted by citations
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · see citing works
“assessed the variations in CTCs in 117 breast cancer patients and observed a considerable decline in CTCpositive rate after chemotherapy [149].”
BackgroundBidard, F., Peeters, D. J. E., Fehm, T. N., Nolè, F., Gisbert‐Criado, R., Mavroudis, D., Grisanti, S., Generali, D., García-Sáenz, J. Á., Stebbing, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70069-5 · Cited by 842 · see citing works
Self-citationLarsson, A.-M., Jansson, S., Bendahl, P., Jørgensen, C. L. T., Loman, N., Graffman, C., Lundgren, L., Aaltonen, K. E., & Rydén, L. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0976-0 · Cited by 121 · see citing works
“The prognostic value of CTC count in patients with MBC has been confirmed at the highest level of evidence [15] in a pooled analysis; however, previous studies evaluating CTC enumeration in patients with newly diagnosed MBC are sparse and have mainly focused on its prognostic value at baseline [12] or first follow up…”
ResultYan, W.-T., Cui, X., Chen, Q., Li, Y.-F., Cui, Y.-H., Wang, Y., & Jiang, J. (2017) · Scientific Reports · doi:10.1038/srep43464 · Cited by 113 · see citing works
Importance of circulating tumor cells in newly diagnosed colorectal cancer
van Dalum, G., Stam, G.-J., Scholten, L. F. A., MASTBOOM, W. J. B., Vermes, I., Tibbe, A. G. J., de Groot, M. R., & Terstappen, L. W. M. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2824 · Cited by 112 · see citing works
Wallwiener, M., Riethdorf, S., Hartkopf, A. D., Modugno, C., Nees, J., Madhavan, D., Sprick, M. R., Schott, S., Domschke, C., Baccelli, I., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-512 · Cited by 77 · see citing works
“Data from this and other studies [5,8,9,16,17] do not allow the distinction between breast cancers with unfavorable CTC kinetics that are resistant to the specific type of chemotherapy administered versus those that are resistant to chemotherapy in general.”
Lv, Q., Gong, L., Zhang, T., Ye, J., Chai, L., Ni, C., & Mao, Y. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1372-1 · Cited by 76 · see citing works
“[34] also reported that MBC patients with 0–4 CTCs after first-line chemotherapy had a significantly better PFS and OS than those with C5 CTCs after first-line chemotherapy, and patients with C5 CTCs at baseline and\5 CTCs after firstline chemotherapy had similar OS to those who had \5 CTC at baseline.”
ResultClinical indications for, and the future of, circulating tumor cells
Moon, D. H., Lindsay, D. P., Hong, S., & Wang, A. Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.002 · Cited by 71 · see citing works
Addanki, S., Meas, S., Sarli, V. N., Singh, B., & Lucci, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147843 · Cited by 45 · see citing works
“sought to analyze the relationship between OS and CTC counts after the first round of chemotherapy [62].”
BackgroundCirculating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Magbanua, M. J. M., Carey, L., DeLuca, A. N., Hwang, J., Scott, J. H., Rimawi, M. F., Mayer, E. L., Marcom, P. K., Liu, M., Esteva, F. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1948 · Cited by 42 · see citing works
The significance of circulating tumour cells in breast cancer: A review
Castle, J., Shaker, H., Morris, K. L., Tugwood, J. D., & Kirwan, C. (2014) · The Breast · doi:10.1016/j.breast.2014.07.002 · Cited by 40 · see citing works
“In MBC, the presence of 5 CTC prior to second cycle of chemotherapy is associated with reduced progression free and overall survival [29].”
BackgroundCorrenti, M., & Raggi, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12569 · Cited by 40 · see citing works
“melanoma [116], pancreatic [117], prostate [118, 119] breast [120-122], lung [123, 124] gastric [125] and colorectal cancer [126, 127]).”
BackgroundReduzzi, C., Nicolò, E., Singhal, S., Venetis, K., Franco, A. O., de Miguel‐Pérez, D., Dipasquale, A., Gouda, M. A., Saldanha, E. F., Kasi, P. M., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104483 · Cited by 25 · see citing works
Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
Turner, N. H., Pestrin, M., Galardi, F., Luca, F. D., Malorni, L., & Leo, A. D. (2014) · Cancers · doi:10.3390/cancers6020684 · Cited by 24 · see citing works
“, CTC count after the 1st cycle of chemotherapy was the only independent factor significantly associated with OS or PFS [15].”
BackgroundBanys-Paluchowski, M. J., Fehm, T. N., Grimm, D., Rody, A., & Krawczyk, N. (2021) · Oncology Research and Treatment · doi:10.1159/000520561 · Cited by 24 · see citing works
Circulating and Disseminated Tumor Cells in Breast Carcinoma
Banys-Paluchowski, M. J., Fehm, T. N., Janni, W., Solomayer, E., & Hartkopf, A. D. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1031-1120 · Cited by 21 · see citing works
“measured CTCs in patients receiving palliative chemotherapy and reported that CTC numbers after the first cycle of treatment were associated with response to therapy and survival in the multivariate analysis [32].”
Liquid Biopsy in Breast Cancer
Banys‐Paluchowski, M., Krawczyk, N., & Fehm, T. N. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1124-7225 · Cited by 20 · see citing works
“were able to demonstrate that after the first cycle of therapy < 5 CTCs were detected in 47–57% of patients with initial counts of ≥ 5 CTCs [51, 52].”
BackgroundInterrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Xue, J., Xie, V. K., Wang, P., Cui, J., Gao, Y., & Lu, Z. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140128220152 · Cited by 16 · see citing works
O’Toole, S. A., Spillane, C. D., Huang, Y., Fitzgerald, M. C., Ffrench, B., Mohamed, B. M., Ward, M. P., Gallagher, M. F., Kelly, T. E., O’Brien, C. P., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05658-7 · Cited by 15 · see citing works
Netterberg, I., Karlsson, M. O., Terstappen, L. W. M. M., Koopman, M., Punt, C. J. A., & Friberg, L. E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2570 · Cited by 13 · see citing works
Szostakowska-Rodzoś, M., Fabisiewicz, A., Wakuła, M., Tabor, S., Szafron, L. M., Jagiełło-Gruszfeld, A., & Grzybowska, E. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-63679-4 · Cited by 12 · see citing works
“High CTC counts in metastatic breast cancer were previously reported as prognostic for PFS and OS 21–24 , however, some trials fail to demonstrate the clinical utility of CTC monitoring 25 .”
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
Banys‐Paluchowski, M., Reinhardt, F., & Fehm, T. N. (2020) · Applied Sciences · doi:10.3390/app10093311 · Cited by 12 · see citing works
“In the multivariate analysis, response to therapy and survival was associated with CTC counts after the first cycle of therapy [9].”
MethodLatest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer
Munoz-Arcos, L. S., Nicolò, E., Serafini, M. S., Gerratana, L., Reduzzi, C., & Cristofanilli, M. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.005 · Cited by 12 · see citing works
Echarri, A. A., Beresford, M. J., Campbell, J. P., Jones, R. H., Butler, R., Gollob, K. J., Brum, P. C., Thompson, D., & Turner, J. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.616188 · Cited by 11 · see citing works
Egorova, A., Pyankov, I., Maretina, M. A., Баранов, В. С., & Kiselev, A. (2021) · Pharmaceuticals · doi:10.3390/ph14100957 · Cited by 10 · see citing works
“The level of cell proliferative activity is known to determine the aggressiveness and malignancy of the tumor process [48].”
BackgroundClinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer
Bañuelos, J., López, C. R., Cortegoso, A., Ozores, P. P., & Garcia, T. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35805-1_10 · Cited by 8 · see citing works
Review: circulating tumor cells in the practice of breast cancer oncology
Ramos‐Medina, R., Moreno, F., López‐Tarruella, S., del Monte-Millán, M., Márquez‐Rodas, I., Durán, E., Jerez, Y., García-Sáenz, J. Á., Ocaña, I., Andrés, S., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1460-2 · Cited by 7 · see citing works
Self-citationMorales, S. M., Velasco, A., Gasol, A., Córdoba, F. M., Vidal-Martínez, J., Serrate, A., Valls, J., Pérez-Vargas, J. C. S., Gisbert‐Criado, R., Moral, D., et al. (2018) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2018.04.003 · Cited by 5 · see citing works
Han, T., Zhang, J., Xiao, D., Yang, B., Chen, L., Zhai, C., Ding, F., Xu, Y., Zhao, X., & Zhao, J. (2022) · Journal of Oncology · doi:10.1155/2022/5247423 · Cited by 4 · see citing works
“For patients receiving palliative chemotherapy, CTCs numbers after the first cycle of treatment showed strong relevance to the therapeutic response [15].”
BackgroundCirculating tumor cells in metastatic breast cancer: ready for clinical practice?
(2022) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2022.007 · Cited by 3 · see citing works
“Besides this, increasing CTC numbers under palliative chemotherapy indicate a higher risk of disease progression [4, 14].”
BackgroundRole of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
Hall, C. S., Sarli, V. N., Meas, S., & Lucci, A. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-0308-0 · Cited by 2 · see citing works
Shao, B., Li, H., Zhang, J., Liu, X., Song, G., Jiang, H., Yan, Y., Wang, H., Wang, J., & Di, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3797 · Cited by 2 · see citing works
“Since then, several studies had found similar results (2-12).”
ResultDetection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer
Kwa, M. J., & Esteva, F. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00066-0 · Cited by 2 · see citing works
Breast cancer stem cells and circulating tumor cells: Dual drivers of progression and relapse
Azizi, Z., Urgancı, B. E., & Açıkbaş, İ. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i12.112990 · Cited by 1 · see citing works
Clinical relevance of circulating tumor cells in cancer patients
Hamilton, G. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0237-1 · Cited by 1 · see citing works
Liquid Biopsy beim Mammakarzinom
Banys‐Paluchowski, M., Krawczyk, N., & Fehm, T. N. (2021) · TumorDiagnostik & Therapie · doi:10.1055/a-1467-0165 · Cited by 1 · see citing works
“Zyklus der Therapie < 5 CTCs detektiert werden konnten [51, 52].”
BackgroundBone Marrow Micrometastases and Circulating Tumor Cells
Kılıçkap, S., Aktaş, B. Y., & Ozisik, Y. Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-04606-4_13 · Cited by 1 · see citing works
Bone Marrow Micrometastases and Circulating Tumor Cells
Kılıçkap, S., Altundag, M. K., & Ozisik, Y. Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-22843-3_12
Liquid Biopsy beim Mammakarzinom
Banys‐Paluchowski, M., Krawczyk, N., & Fehm, T. N. (2021) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1678-1129
Netterberg, I., Karlsson, M. O., Terstappen, L. W. M. M., Koopman, M., Punt, C. J. A., & Friberg, L. E. (2023) · doi:10.1158/1078-0432.22475168
Jha, S., Singh, C., Singh, V. P., Shekhawat, L. K., & Raghunandan, M. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119353
- Authors
- Martín, M., Custodio, S., Casas, M.-L. M., García-Sáenz, J.-Á., Torre, J.-C., Bellón-Cano, J.-M., López-Tarruella, S., Vidaurreta-Lazaro, M., Orden, V., Jerez, Y., Márquez-Rodas, I., Casado, A., Sastre, J., & Díaz-Rubio, E.
- Affiliations
- Universidad Complutense de Madrid (ES)
- Medical Oncology Service, Hospital Universitario San Carlos, Universidad Complutense, Madrid, Spain
- Department of Statistics, Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Universidad Complutense, Madrid, Spain;
- Medical Oncology Service, Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Universidad Complutense, Madrid, Spain;
- Clinical Analysis Service, Hospital Universitario San Carlos, Universidad Complutense, Madrid, Spain
- Corresponding author
- Martín, Miguel
- ORCID
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-19
- Volume
- 18
- Issue
- 8
- Pages
- 917-923
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3755928
- OpenAlex
- W2138168632
- Cited by
- 41
- References
- 9
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 5 · 2014: 6
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Comillas Repository (Comillas Pontifical University) (submittedVersion, cc-by-nc-nd)
- Funders
- FEDER (RTICC-RD12/0036/0076)
- Spanish National Network of Cancer Centers (RTICC, RD06/0020/0021)
- Accion Transversal del Cancer-Instituto Carlos III
- Fundación Mutua Madrileña
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- circulating tumor cells, metastatic breast cancer, prognostic factors, overall survival, progression-free survival, clinical benefit rate, chemotherapy response, early treatment response prediction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Neoplastic Cells, Circulating, Prognosis, Biomarkers, Tumor, Survival Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
